期刊文献+

CT影像磨玻璃样结节中实性成分对肺腺癌的诊断价值分析 被引量:6

Clinical value of solid components in ground glass nodule of CT in the diagnosis of lung adenocarcinoma
原文传递
导出
摘要 目的分析CT影像磨玻璃样结节(GGN)中实性成分对肺腺癌的诊断价值。方法回顾性分析宁波市第四医院2017年1月至2019年3月收治的肺腺癌确诊患者217例的CT影像,按病灶性质分为浸润前组、微浸润腺癌(MIA)组及浸润性腺癌(IAC)组,分析各组GGN中实性成分比例、大小、形态等,并对数据进行统计分析。结果浸润前病变组、MIA组和IAC组GGN实性成分均值分别为(1.02±0.73)mm、(3.76±1.22)mm和(10.22±4.06)mm,实性层面直径分别为(0.91±0.65)mm、(3.45±1.37)mm和(10.18±4.41)mm,最大径分别为(1.10±0.81)mm、(5.16±1.60)mm、(11.96±5.17)mm,单发比例分别为87.18%(34/39)、34.12%(29/85)和27.96%(26/93),中心性生长率分别为66.67%(26/39)、22.35%(19/85)和32.26%(30/93),点状率分别为79.49%(31/39)、76.47%(65/85)和44.09%(41/93),边界清晰率分别为20.51%(8/39)、28.24%(24/85)和41.94%(39/93)。三组间GGN实性成分均值、实性层面直径、最大径、数量、生长部位、形态及边界比较,差异均有统计学意义(F或χ^2值分别为196.362、173.605、154.91、42.582、23.594、25.474和7.004,均P<0.05)。结论CT影像GGN中实性成分表现有助于肺腺癌病理类型的鉴别,可作为术前参考加以应用。
作者 朱红霞 张光辉 林平 Zhu Hongxia;Zhang Guanghui;Lin Ping(Department of Radiology,the Fourth Hospital of Ningbo,Ningbo,Zhejiang 315700,China)
出处 《中国基层医药》 CAS 2020年第9期1128-1130,共3页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献12

二级参考文献128

  • 1吕真,倪国华.吉非替尼三线治疗晚期非小细胞肺癌临床观察[J].实用癌症杂志,2010,25(5):528-529. 被引量:4
  • 2李易霞,吴重重,李智勇,伍建林.基于CT征象鉴别肺部磨玻璃结节良恶性的临床研究[J].中华临床医师杂志(电子版),2011,5(23):7151-7153. 被引量:14
  • 3刘士远,肖湘生.孤立性肺结节的处理策略[J].中华放射学杂志,2005,39(1):6-8. 被引量:93
  • 4Schiller JH,Harrington D,Belani CP,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med,2002,346:92-98.
  • 5Scagliotti GV,Parikh P,von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.J Clin Oncol,2008,26:3543-3551.
  • 6Desai N,Trieu V,Yao Z,et al.Increased antitumor activity,intratumor paclitaxel concentrations,and endothelial cell transport of cremophor-free,albumin-bound paclitaxel,ABI-007,compared with cremophor-based paclitaxel.Clin Cancer Res,2006,12:1317-1324.
  • 7Socinski MA,Bondarenko I,Karaseva NA,et al.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer:final results of a phase Ⅲ trial.J Clin Oncol,2012,30:2055-2062.
  • 8Okamoto I,Fukuoka M.S-1:a new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer.Clin Lung Cancer,2009,10:290-294.
  • 9Yoshioka H,Okamoto I,Morita S,et al.Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer:updated results of the West Japan Oncology Group LETS study.Ann Oncol,2013,24:1326-1331.
  • 10PirkerR,Pereira JR,Szczesna A,et al.Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX):an open-label randomised phase Ⅲ trial.Lancet,2009,373:1525-1531.

共引文献131

同被引文献66

引证文献6

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部